Serina Therapeutics Inc (SER) - Total Liabilities
Based on the latest financial reports, Serina Therapeutics Inc (SER) has total liabilities worth $10.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Serina Therapeutics Inc (SER) equity growth momentum to track the company's year-over-year net asset growth rate.
Serina Therapeutics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Serina Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Serina Therapeutics Inc (SER) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Serina Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Serina Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
InfoBank Corporation
KQ:039290
|
Korea | ₩28.87 Billion |
|
BMG Resources Ltd
AU:BMG
|
Australia | AU$76.70K |
|
Mhethanol Co. Ltd.
KO:023150
|
Korea | ₩198.60 Billion |
|
Alphawave IP Group PLC
LSE:AWE
|
UK | GBX657.59 Million |
|
Coats Group PLC
LSE:COA
|
UK | GBX1.24 Billion |
|
Matichon Public Company Limited
BK:MATI
|
Thailand | ฿326.22 Million |
|
Zenta Group Company Limited
NASDAQ:ZTG
|
USA | $429.97K |
|
Nagarjuna Fertilizers and Chemicals Limited
NSE:NAGAFERT
|
India | Rs13.32 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Serina Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Serina Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.98 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Serina Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Serina Therapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Serina Therapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.22 Million | -84.94% |
| 2023-12-31 | $41.26 Million | +100.73% |
| 2022-12-31 | $20.56 Million | +36.78% |
| 2021-12-31 | $15.03 Million | +61.24% |
| 2020-12-31 | $9.32 Million | +93.18% |
| 2019-12-31 | $4.83 Million | +97.75% |
| 2018-12-31 | $2.44 Million | +85.98% |
| 2017-12-31 | $1.31 Million | -94.87% |
| 2016-12-31 | $25.60 Million | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more